Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LIFELINE SCIENTIFIC INC. We currently have 11 research reports from 1 professional analysts.
|08Dec16 16:58||RNS||CLOSING OF THE MERGER - CANCELLATION FROM AIM|
|10Nov16 07:00||RNS||Date of merger closing and cancellation|
|06Oct16 15:18||RNS||RESULTS OF SPECIAL MEETING|
|26Sep16 07:00||RNS||Half-year Report|
|14Sep16 17:13||RNS||Publication of Proxy Statement & Notice of Meeting|
|02Sep16 07:01||RNS||Recommended Cash Acquisition|
|02Sep16 07:00||RNS||Trading update|
Frequency of research reports
Research reports on
LIFELINE SCIENTIFIC INC
LIFELINE SCIENTIFIC INC
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Panmure Morning Note 26-09-2016
26 Sep 16
Following the company’s statement on 2 September 2016 (recommended cash acquisition, trading update) the company has issued interim results this morning. Given the ongoing process set in train following the announcement of the definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) (02 September 2016) we retain our recommendation and forecasts Under Review.
Panmure Morning Note 02-09-2016
02 Sep 16
This morning Lifeline Scientific has announced it has entered into a definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) and, separately, released a trading update for the 6 months ending 30 June 2016. The cash offer from SGM values Lifeline Scientific at circa $87.8m or $4.083 in cash per share. If approved the transaction is expected to close in the fourth quarter calendar 2016 and by no later than 9 December 2016. We remind investors that LSI is incorporated in the State of Delaware in the USA and the merger is proposed in accordance with the Delaware General Corporation Law. The acquisition is not subject to the UK City Code on Takeovers and Mergers and is subject to shareholder approval. We retain our recommendation and forecasts Under Review.
Panmure Morning Note 27-4-2016
27 Apr 16
FY15 headline numbers were highlighted in January’s trading update: revenues $39.4m, operating profit $5.7m (2014: $2.4m). Year-end cash $6.9m – company is now debt free having paid off revolver balance of $2.2m by year-end. Strategic review – company is in discussions with interested parties, which may or may not lead to an offer. Usual caveats on outcomes and timing apply, but given the Board expects to provide a further update by end June, we assume Lifeline is probably quite deep into the process and this looks like the lead in terms of possible strategic options.
Panmure Morning Note 19-01-16
19 Jan 16
Further to Lifeline's ahead-of-expectations trading update and announced stocking order ($3.3m) from its principal distributor in China (18 December 2015), the company has today released further detail on the year ending 31 December 2015. While the strategic and financial review announced on 21 September 2015 is still ongoing, strong operational progress is clearly being delivered and the confident tone of the statement is well-deserved. Prelims are expected by the end of April 2016.
Panmure Morning Note 18-12-15
18 Dec 15
This morning Lifeline Scientific announces an update on trading, in advance of a more detailed update scheduled for February, and the receipt of a stocking order from its principal distributor in China worth approximately US$3.3m. The company also announces that it expects revenues for the year ending 31 December 2015 to be ahead of expectations and for adjusted pre-tax profit to be materially ahead of market expectations. A further trading update will be provided in January.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017